<DOC>
	<DOCNO>NCT01429441</DOCNO>
	<brief_summary>The purpose study evaluate treatment symptomatic vitreomacular adhesion / ( VMT ) include macular hole ocriplasmin .</brief_summary>
	<brief_title>Ocriplasmin Treatment Symptomatic Vitreomacular Adhesion Including Macular Hole</brief_title>
	<detailed_description>The present study design assess anatomical functional outcome follow single intravitreal injection ocriplasmin 0.125mg subject symptomatic vitreomacular adhesion ( VMA ) / ( VMT ) include macular hole .</detailed_description>
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Retinal Perforations</mesh_term>
	<criteria>Subjects 18 year age old either gender Presence vitreomacular adhesion Best correct visual acuity ( BCVA ) 20/32 bad study eye BCVA 20/800 good nonstudy eye History current evidence proliferative retinopathy , exudative agerelated macular degeneration ( AMD ) retinal vein occlusion study eye Any vitreous hemorrhage vitreous opacification precludes visualization posterior pole visual inspection OR adequate assessment macula spectraldomain optical coherence tomography ( SDOCT ) study eye Macular hole &gt; 400 Âµm diameter study eye Presence epiretinal membrane ( ERM ) Aphakia study eye High myopia ( 8D ) study eye History rhegmatogenous retinal detachment either eye History vitrectomy study eye Previous participation trial prior administration ocriplasmin study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>